Philosophy of Care
Dr. Valicenti believes in being tough on cancer through use of the best therapeutic weapons and a team's approach to maximize the outcomes while preventing side effects. It is also important to be an innovator to advance new cancer treatments and to be an educator for all patients and the next-generation of cancer care givers. Dr. Valicenti is nationally and internationally recognized in prostate cancer and other tumors.
Dr. Valicenti's clinical interests focus on prostate cancer, gynecologic tumors, genitourinary malignancies, and brain tumors. He is also interested in prostate seed implant and Gamma Knife.
Currently, Dr. Valicenti is conducting clinical trial research evaluating multi-modality therapies for clinically localized prostate cancer. In addition, he is carrying out outcome based studies addressing quality of life questions and exploratory analyses of large databases.
4501 X St.
Sacramento, CA 95817
M.A., Columbia University Graduate School, New York, New York, 1984
B.S., Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, 1981
American Society of Therapeutic Radiology and Oncology
Select Recent Publications:
Li B, Shi XB, Nori D, Chao CK, Chen AM, Valicenti R, White Rde V. Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate. 2011 May;71(6):567-74. doi: 10.1002/pros.21272. Epub 2010 Sep 28.
Perks J, Turnbull H, Liu T, Purdy J, Valicenti R. Vector analysis of prostate patient setup with image-guided radiation therapy via kV cone beam computed tomography. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):915-9. Epub 2010 Jul 17.
Perks JR, Stanic S, Stern RL, Henk B, Nelson MS, Harse RD, Mathai M, Purdy JA, Valicenti RK, Siefkin AD, Chen AM. Failure Mode and Effect Analysis for Delivery of Lung Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2011 Dec 22. [Epub ahead of print]
Stanic S, Mathai M, Cui J, Purdy JA, Valicenti RK. Relationship Between Pelvic Organ-at-Risk Dose and Clinical Target Volume in Postprostatectomy Patients Receiving Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Apr 30. [Epub ahead of print]
Valicenti RK, Bae K, Michalski J, Sandler H, Shipley W, Lin A, Cox J. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1323-9.
Valicenti RK, Trabulsi E, Intenzo C, Lavarino J, Xu Y, Chervoneva I. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):732-7. Epub 2010 Apr 14.
Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD. Long-Term Toxicity Following 3D Conformal Radiation Therapy for Prostate Cancer from the RTOG 9406 Phase I/II Dose Escalation Study. Int J Radiat Oncol Biol Phys, 76(1): 14-22. 2010
Gomella LG, Lin J, Hoffman-Censits J, Dugan P, Guiles F, Lallas CD, Singh J, McCue P, Showalter T, Valicenti RK, Dicker A, Trabulsi EJ. Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract. 2010 Nov;6(6):e5-e10.